ESPR
NASDAQEsperion Therapeutics Inc.
Price$3.19+0.88 (+38.10%)
2026-04-072026-07-10
News · 26 weeks75+100%
2026-04-192026-10-11
Mix490d
- Other4(100%)
Latest news
25 items- PREsperion Reaches Settlement Agreement with Sixth ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) & NEXLIZET® (bempedoic acid & ezetimibe) Prior to April 19, 2040ANN ARBOR, Mich., Oct. 07, 2026 (GLOBE NEWSWIRE) -- Esperion, a company wholly-owned by ARCHIMED, today announced that it has entered into a settlement agreement with Renata Limited (along with an affiliate). This agreement resolves the patent litigation brought by Esperion against Renata in response to Renata’s Abbreviated New Drug Applications (ANDAs) seeking approval to market generic versions of NEXLETOL and NEXLIZET prior to the expiration of the applicable patents. Pursuant to the agreement, Renata has agreed not to market a generic version of either NEXLETOL or NEXLIZET in the United States prior to April 19, 2040, unless certain limited circumstances customarily included in these t
- PREsperion Therapeutics Offers Short-Term Option for Diuretic Management Before Escalation to IV for Patients With Heart Failure– Loop Diuretic Route of Administration Option Is Delivered As A Single-Use Nasal Spray – – Nasal Route Offers a Direct Path to Systemic Absorption Without Relying on the GI Tract – ANN ARBOR, Mich., Sept. 30, 2026 (GLOBE NEWSWIRE) -- With more than six million Americans living with heart failure and healthcare systems increasingly focused on delivering care beyond traditional care settings, Esperion, a company wholly-owned by ARCHIMED, is launching a nationwide effort to raise awareness of ENBUMYST™ (bumetanide nasal spray), a short-term nasal diuretic indicated for the treatment of edema associated with congestive heart failure. As the healthcare landscape prepares for the implementati
- SECSEC Form SCHEDULE 13G filed by Esperion Therapeutics Inc.SCHEDULE 13G - Esperion Therapeutics, Inc. (0001434868) (Subject)
- SECSEC Form 15-12G filed by Esperion Therapeutics Inc.15-12G - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECSEC Form EFFECT filed by Esperion Therapeutics Inc.EFFECT - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECSEC Form EFFECT filed by Esperion Therapeutics Inc.EFFECT - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECSEC Form EFFECT filed by Esperion Therapeutics Inc.EFFECT - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECSEC Form EFFECT filed by Esperion Therapeutics Inc.EFFECT - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECSEC Form EFFECT filed by Esperion Therapeutics Inc.EFFECT - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECSEC Form EFFECT filed by Esperion Therapeutics Inc.EFFECT - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Esperion Therapeutics Inc.SCHEDULE 13G/A - Esperion Therapeutics, Inc. (0001434868) (Subject)
- INSIDERDirector Hoffman Robert E. returned 85,153 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover withholding tax4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- INSIDERDirector Carroll J Martin returned 177,523 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover withholding tax4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- INSIDERDirector Shepard Jay returned 164,472 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy tax liability4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- INSIDERDirector Fischer Seth H. Z. returned 141,023 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- INSIDERDirector Thompson John Craig returned 79,873 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- INSIDERChief Commercial Officer Harlow John B. Jr. returned 424,536 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- INSIDERChief Legal Officer Looker Benjamin returned 667,524 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- INSIDERChief Financial Officer Halladay Benjamin returned 705,410 shares to the company, closing all direct ownership in the company (SEC Form 4) (for tax liability)4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- INSIDERPresident and CEO Koenig Sheldon L. returned 2,121,094 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)4 - Esperion Therapeutics, Inc. (0001434868) (Issuer)
- SECSEC Form POSASR filed by Esperion Therapeutics Inc.POSASR - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECSEC Form POS AM filed by Esperion Therapeutics Inc.POS AM - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECSEC Form POS AM filed by Esperion Therapeutics Inc.POS AM - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECSEC Form POS462B filed by Esperion Therapeutics Inc.POS462B - Esperion Therapeutics, Inc. (0001434868) (Filer)
- SECSEC Form POS AM filed by Esperion Therapeutics Inc.POS AM - Esperion Therapeutics, Inc. (0001434868) (Filer)
ESPR FAQ
7 questionsWhat does Esperion Therapeutics Inc. do?
Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low-density lipoprotein cholesterol in the United States and internationally. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. The company has a license and collaboration agreement with Daiichi Sankyo Europe GmbH; and Serometrix to in-license its oral, small molecule PCSK9...Where does ESPR stock trade?
Esperion Therapeutics Inc. (ESPR) is listed on NASDAQ.What sector and industry is ESPR in?
Esperion Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Esperion Therapeutics Inc. go public?
Esperion Therapeutics Inc. (ESPR) completed its IPO in 2013.What are analysts saying about ESPR?
Esperion Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from H.C. Wainwright: Neutral on 2026-05-01. Recent price targets range from $250.00 to $900.00.What companies are similar to ESPR?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare ESPR side-by-side with any of them on Quantisnow.How can I track ESPR on Quantisnow?
Quantisnow aggregates Esperion Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow ESPR to receive live email and push alerts on every new disclosure.